When I look at India’s drug landscape today, I see an sector that has grown above the low-cost medicine production. Our India is really famous for generic drugs, vaccines, APIs, contract manufacturing, biosimilars, and other advanced medicines.
India is the 3rd largest pharmaceutical manufacturer in the world by volume and 11th by value. Our Country has 3,000 + pharma companies and 10,500 manufacturing units. Pharma exports have reached about US$30.5 billion in FY2024–25.
Indian medicines are also sold in more than 190 countries. This makes India an important part of the global medicine supply chain.
Why Is India’s Drug Sector Growing?
One of India’s main strengths is its large manufacturing base. The country has thousands of pharma plants and many US FDA-approved manufacturing sites.
Cost is another major reason for India’s growth. Indian companies may produce medicines at low costs because the country has better and large supplier network, workers with skills, and a strong pharma industry.
Demand for medicines is also growing in India. Now a days many people are becoming aware of healthcare and health insurance. Urban areas and an ageing population are also increasing healthcare needs.
At the same time, diseases such as diabetes, cancer, and heart disease are becoming more common. This is increasing the need for long-term treatment and medicines.
Indian government support is also helping the market.
According to Towards Healthcare Research and Consulting, the global drugs market was valued at US$1,688.14 billion in 2025. It is expected to reach US$1,790.05 billion in 2026 and nearly US$3,034.63 billion by 2035, growing at a CAGR of 6.04%.
India’s Leading Pharmaceutical Companies
India has many pharma companies with a strong presence in both India and other countries.
Sun Pharmaceutical Industries is largest pharma company by revenue in India. It has a strong business in specialty medicines, generics, and complex products.
Cipla is well known for respiratory medicines. It also provides affordable medicines in India and other developing markets.
Aurobindo Pharma has strong capabilities in generic medicines and APIs. Lupin has a major presence in respiratory, heart disease, diabetes, and other treatment areas.
Other major companies include Zydus Lifesciences, Torrent Pharmaceuticals, Alkem Laboratories, Mankind Pharma, Biocon, and Divi’s Laboratories.
Each company is following a different path. Many generates special medicines, while other companies are growing in complex generics, APIs, biosimilars, vaccines, or overseas markets.
Where I See the Biggest Opportunities
India’s pharma industry has generated strong opportunities in areas like complex generics, biosimilars, APIs, specialty medicines, and contract manufacturing. Growing demand in world can help Indian CDMOs, CROs, and drug manufacturers to expand internationally. Simultaneously, stronger R&D and different global supply chains can create new growth opportunities for India.
What are the Challenges that Cannot Be Ignored
- Strong price competition: Generic medicines face high price challenges in many markets.
- Strict rules: Companies that sell medicines in the countries like US, Europe, and other markets have to follow strict rules.
- API imports: India still depends on China for many APIs and raw materials.
- Higher costs: Energy, raw materials, quality checks and well-skilled workers can increase production costs.
- High research costs: Developing a good quality medicine needs a lot of money and can take lot of years.
- Quality issues: A quality or manufacturing problem can affect a company’s reputation and business.
My View
I believe India’s pharma sector is entering a new stage. The country is not only known only for making affordable generic medicines.
India already created a strong manufacturing foundation, better workers, large domestic demand, and a global reach. Now next step is to build stronger capabilities in complex medicines, biosimilars, APIs, research, and new drug development.
If Indian pharma companies continue to invest in really better quality, research, technology, and skilled talent, India can strengthen its position in the global pharmaceutical industry.
